TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer

被引：0
|
作者：
McArthur, Heather
Tolaney, Sara
Loibl, Sibylle
Dent, Rebecca
Schmid, Peter
Asselah, Jamil
Song, Erwei
Niikura, Naoki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-20-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-20-13
引用
收藏
页数：3
相关论文
共 36 条
  • [21] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Karantza, V.
    Zhao, J.
    Aktan, G.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 853 - 854
  • [22] A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
    Harbeck, Nadia
    Boileau, Jean-Francois
    Modi, Shanu
    Kelly, Catherine M.
    Ohno, Shinji
    Wu, Jiong
    Brekenridge, Mark
    Herbolsheimer, Pia
    Yu, Tinghui
    Pusztai, Lajos
    CANCER RESEARCH, 2022, 82 (04)
  • [23] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Mouret-Reynier, Marie-Ange
    Ferreira, Marta
    Im, Seock-Ah
    Cardoso, Fatima
    Ding, Yu
    Pan, Wilbur
    Tryfonidis, Konstantinos
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [24] A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+early stage triple negative breast cancer (eTNBC) to assess safety and immune response
    Isakoff, Steven J.
    Adams, Sylvia
    Soliman, Hatem H.
    Tung, Nadine
    Barry, William T.
    Hu, Jiani
    Trippa, Lorenzo
    Deering, Rachel
    Parker, Joanne
    Park, Hannah
    Brachtel, Elena F.
    Ellisen, Leif W.
    Severgnini, Mariano
    Peterkin, Doris
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
    Aoyama, Yosuke
    Ozaki, Yukinori
    Kizawa, Rika
    Masuda, Jun
    Kawai, Saori
    Kurata, Mami
    Maeda, Tetsuyo
    Yoshida, Kazuyo
    Yamashita, Nami
    Nishimura, Meiko
    Hosonaga, Mari
    Fukada, Ippei
    Hara, Fumikata
    Kobayashi, Takayuki
    Takano, Toshimi
    Ueno, Takayuki
    BREAST CANCER, 2025, 32 (02) : 329 - 336
  • [26] Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) plus /durvalumab (durva) plus /- oleclumab (ole) combined with neoadjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2-breast cancer (BC)
    De Caluwe, A.
    Desmoulins, I.
    Cao, K.
    Remouchamps, V.
    Baten, A.
    Longton, E.
    Peignaux-Casasnovas, K.
    Nader-Marta, G.
    Arecco, L.
    Agostinetto, E.
    Kristanto, P.
    Catteau, X.
    Larsimont, D.
    Salgado, R. F.
    Sotiriou, C.
    Poortmans, P.
    Piccart, M.
    Ignatiadis, M.
    Romano, E.
    Buisseret, L.
    ANNALS OF ONCOLOGY, 2024, 35 : 1205 - 1205
  • [27] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Harbeck, Nadia
    Bourayou, Nawel
    Frenzel, Martin
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [28] KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
    Hirshfield, Kim
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David
    McArthur, Heather
    Telli, Melinda
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Karantza, Vassiliki
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S288 - S288
  • [29] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
    Cardoso, F.
    McArthur, H. L.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    O'Shaughnessy, J.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Fernandez, M. E. Gonzalez
    Liu, Z.
    Yasojima, H.
    Ding, Y.
    Jia, L.
    Karantza, V. V.
    Tryfonidis, K. E.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
  • [30] Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
    Harbeck, Nadia
    Barrios, Carlos
    Zhang, Amy
    Saji, Shigehira
    Jung, Kyung Hae
    Hegg, Roberto
    Koehler, Andreas
    Sohn, Joo Hyuk
    Iwata, Hiroji
    Telli, Melinda
    Boileau, J. -F.
    Punie, Kevin
    Dieterich, Max
    Assaf, Zoe
    Xu, Trista
    Hermoso, Mario Liste
    Shearer-Kang, Esther
    Molinero, Luciana
    Chui, Stephen
    Mittendorf, Elizabeth
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 30 - 30
1234